Top

Published in:

Open Access 01-12-2023 | Research

Development and validation of a kidney renal clear cell carcinoma prognostic model relying on pyroptosis-related LncRNAs-A multidimensional comprehensive bioinformatics exploration

Authors: Chang Liu, Shuxin Dai, Hao Geng, Zhiwei Jiang, Xiangyu Teng, Kun Liu, Zhouting Tuo, Longfei Peng, Chao Yang, Liangkuan Bi

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

Renal cell carcinoma (RCC) is a malignant tumour that may develop in the kidney. RCC is one of the most common kinds of tumours of this sort, and its most common pathological subtype is kidney renal clear cell carcinoma (KIRC). However, the aetiology and pathogenesis of RCC still need to be clarified. Exploring the internal mechanism of RCC contributes to diagnosing and treating this disease. Pyroptosis is a critical process related to cell death. Recent research has shown that pyroptosis is a critical factor in the initiation and progression of tumour formation. Thus far, researchers have progressively uncovered evidence of the regulatory influence that long noncoding RNAs (lncRNAs) have on pyroptosis.

Methods

In this work, a comprehensive bioinformatics approach was used to produce a predictive model according to pyroptosis-interrelated lncRNAs for the purpose of predicting the overall survival and molecular immune specialties of patients diagnosed with KIRC. This model was verified from multiple perspectives.

Results

First, we discovered pyroptosis-associated lncRNAs in KIRC patients using the TCGA database and a Sankey diagram. Then, we developed and validated a KIRC patient risk model based on pyroptosis-related lncRNAs. We demonstrated the grouping power of PLnRM through PCA and used PLnRM to assess the tumour immune microenvironment and response to immunotherapy. Immunological and molecular traits of diverse PLnRM subgroups were evaluated, as were clinical KIRC patient characteristics and predictive risk models. On this basis, a predictive nomogram was developed and analyzed, and novel PLnRM candidate compounds were identified. Finally, we investigated possible medications used by KIRC patients.

Conclusions

The results demonstrate that the model generated has significant value for KIRC in clinical practice.

Available only for authorised users

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810. https://doi.org/10.1016/j.eururo.2019.02.011.CrossRefPubMed

Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, et al. Management of small renal masses: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(6):668. https://doi.org/10.1200/JCO.2016.69.9645.CrossRefPubMed

Ge W, Song S, Qi X, Chen F, Che X, Sun Y, et al. Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma. Oncol Res. 2023;31(3):255–70. https://doi.org/10.32604/or.2023.027942.CrossRefPubMedPubMedCentral

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. https://doi.org/10.1056/NEJMoa1510665.CrossRefPubMedPubMedCentral

Zeng SY, Liu YF, Liu JH, Zeng ZL, Xie H, Liu JH. Potential effects of Akkermansia Muciniphila in aging and aging-related diseases: current evidence and perspectives. Aging Dis. 2023. https://doi.org/10.14336/AD.2023.0325.CrossRefPubMedPubMedCentral

Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417–26. https://doi.org/10.1016/s1097-2765(02)00599-3.CrossRef

Hersh D, Monack DM, Smith MR, Ghori N, Falkow S, Zychlinsky A. The Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1. Proc Natl Acad Sci U S A. 1999;96(5):2396–401. https://doi.org/10.1073/pnas.96.5.2396.CrossRefPubMedPubMedCentral

Brennan MA, Cookson BT. Salmonella induces macrophage death by caspase-1-dependent necrosis. Mol Microbiol. 2000;38(1):31–40. https://doi.org/10.1046/j.1365-2958.2000.02103.x.CrossRefPubMed

Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9(3):113–4. https://doi.org/10.1016/s0966-842x(00)01936-3.CrossRefPubMed

10.

Tsuchiya K. Switching from apoptosis to pyroptosis: gasdermin-elicited inflammation and antitumor immunity. Int J Mol Sci. 2021;22(1):426. https://doi.org/10.3390/ijms22010426.CrossRefPubMedPubMedCentral

11.

Zhang Z, Lieberman J. Lighting a fire on the reef. Sci Immunol. 2020;5(54):eabf0905. https://doi.org/10.1126/sciimmunol.abf0905.CrossRefPubMedPubMedCentral

12.

Xu YJ, Zheng L, Hu YW, Wang Q. Pyroptosis and its relationship to atherosclerosis. Clin Chim Acta. 2018;476:28–37. https://doi.org/10.1016/j.cca.2017.11.005.CrossRefPubMed

13.

Pirzada RH, Javaid N, Choi S. The roles of the NLRP3 inflammasome in neurodegenerative and metabolic diseases and in relevant advanced therapeutic interventions. Genes (Basel). 2020;11(2):131. https://doi.org/10.3390/genes11020131.CrossRefPubMedPubMedCentral

14.

Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579(7799):415–20. https://doi.org/10.1038/s41586-020-2071-9.CrossRefPubMedPubMedCentral

15.

Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7(2):99–109. https://doi.org/10.1038/nrmicro2070.CrossRefPubMedPubMedCentral

16.

Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in Oncology. Cell. 2019;179(5):1033–55. https://doi.org/10.1016/j.cell.2019.10.017.CrossRefPubMedPubMedCentral

17.

Gandhi M, Caudron-Herger M, Diederichs S. RNA motifs and combinatorial prediction of interactions, stability and localization of noncoding RNAs. Nat Struct Mol Biol. 2018;25(12):1070–6. https://doi.org/10.1038/s41594-018-0155-0.CrossRefPubMed

18.

Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89. https://doi.org/10.1101/gr.132159.111.CrossRefPubMedPubMedCentral

19.

Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, et al. The transcriptional landscape of the mammalian genome. Science. 2005;309(5740):1559–63. https://doi.org/10.1126/science.1112014.CrossRefPubMed

20.

Wang K, Jin W, Song Y, Fei X. LncRNA RP11-436H11.5, competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335–5p and promotes proliferation and invasion in renal cell carcinoma. Mol Cancer. 2017;16(1):166. https://doi.org/10.1186/s12943-017-0735-3.CrossRefPubMedPubMedCentral

21.

Liu Y, Chen X, Che Y, Li H, Zhang Z, Peng W, Yang J. LncRNAs as the regulators of brain function and therapeutic targets for Alzheimer’s disease. Aging Dis. 2022;13(3):837–51. https://doi.org/10.14336/AD.2021.1119.CrossRefPubMedPubMedCentral

22.

Li X, Zeng L, Cao C, Lu C, Lian W, Han J, et al. Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy. Exp Cell Res. 2017;350(2):327–35. https://doi.org/10.1016/j.yexcr.2016.12.006.CrossRefPubMed

23.

Hu J, Wu H, Wang D, Yang Z, Dong J. LncRNA ANRIL promotes NLRP3 inflammasome activation in uric acid nephropathy through miR-122-5p/BRCC3 axis. Biochimie. 2019;157:102–10. https://doi.org/10.1016/j.biochi.2018.10.011.CrossRefPubMed

24.

Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell. 2013;49(2):331–8. https://doi.org/10.1016/j.molcel.2012.11.009.CrossRefPubMed

25.

Yi H, Peng R, Zhang LY, Sun Y, Peng HM, Liu HD, et al. LincRNA-Gm4419 knockdown ameliorates NF-κB/NLRP3 inflammasome-mediated inflammation in diabetic nephropathy. Cell Death Dis. 2017;8(2):e2583. https://doi.org/10.1038/cddis.2016.451.CrossRefPubMedPubMedCentral

26.

Xu F, Zhan X, Zheng X, Xu H, Li Y, Huang X, et al. A signature of immune-related gene pairs predicts oncologic outcomes and response to immunotherapy in lung adenocarcinoma. Genomics. 2020;112(6):4675–83. https://doi.org/10.1016/j.ygeno.2020.08.014.CrossRefPubMed

27.

Li X, Li Y, Yu X, Jin F. Identification and validation of stemness-related lncRNA prognostic signature for breast cancer. J Transl Med. 2020;18(1):331. https://doi.org/10.1186/s12967-020-02497-4.CrossRefPubMedPubMedCentral

28.

Xu F, Huang X, Li Y, Chen Y, Lin L. m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD. Mol Ther Nucleic Acids. 2021;24:780–91. https://doi.org/10.1016/j.omtn.2021.04.003.CrossRefPubMedPubMedCentral

29.

He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018;37(1):327. https://doi.org/10.1186/s13046-018-1002-1.CrossRefPubMedPubMedCentral

30.

Zeng D, Ye Z, Wu J, Zhou R, Fan X, Wang G, et al. Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics. 2020;10(15):7002–14. https://doi.org/10.7150/thno.46176.CrossRefPubMedPubMedCentral

31.

Hwang S, Kwon AY, Jeong JY, Kim S, Kang H, Park J, et al. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep. 2020;10(1):643. https://doi.org/10.1038/s41598-019-57218-9.CrossRefPubMedPubMedCentral

32.

Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, NY). 2016;352(6282):189–96. https://doi.org/10.1126/science.aad0501.CrossRef

33.

Pang C, Guan Y, Li H, Chen W, Zhu G. Urologic cancer in China. Jpn J Clin Oncol. 2016;46(6):497–501. https://doi.org/10.1093/jjco/hyw034.CrossRefPubMed

34.

Yamamoto K, Ioroi T, Shinomiya K, Yoshida A, Harada K, Fujisawa M, et al. STAT3 polymorphism associates With mTOR inhibitor-induced interstitial lung disease in patients with renal cell carcinoma. Oncol Res. 2022;29(1):11–23. https://doi.org/10.3727/096504022X16418911579334.CrossRefPubMedPubMedCentral

35.

Funakoshi T, Lee CH, Hsieh JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev. 2014;40(4):533–47. https://doi.org/10.1016/j.ctrv.2013.11.008.CrossRefPubMed

36.

Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245–61. https://doi.org/10.1038/s41581-020-00359-2.CrossRefPubMed

37.

Ding J, Wang K, Liu W, She Y, Sun Q, Shi J, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 2016;535:111–6. https://doi.org/10.1038/nature18590.CrossRefPubMed

38.

Broz P, Pelegrin P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020;20:143–57. https://doi.org/10.1038/s41577-019-0228-2.CrossRefPubMed

39.

Yin Y, Li X, Sha X, Xi H, Li YF, Shao Y, et al. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol. 2015;35:804–16. https://doi.org/10.1161/ATVBAHA.115.305282.CrossRefPubMedPubMedCentral

40.

Mamun AA, Wu Y, Nasrin F, Akter A, Taniya MA, Munir F, et al. Role of pyroptosis in diabetes and its therapeutic implications. J Inflamm Res. 2021;14:2187–206. https://doi.org/10.2147/JIR.S291453.CrossRefPubMedPubMedCentral

41.

Jia C, Chen H, Zhang J, Zhou K, Zhuge Y, Niu C, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019;67:311–8. https://doi.org/10.1016/j.intimp.2018.12.028.CrossRefPubMed

42.

Xi G, Gao J, Wan B, Zhan P, Xu W, Lv T, et al. GSDMD is required for effector CD8 T cell responses to lung cancer cells. Int Immunopharmacol. 2019;74:105713. https://doi.org/10.1016/j.intimp.2019.105713.CrossRefPubMed

43.

Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579:415–20. https://doi.org/10.1038/s41586-020-2071-9.CrossRefPubMedPubMedCentral

44.

Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547:99–103. https://doi.org/10.1038/nature22393.CrossRefPubMed

45.

Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21:1346–58. https://doi.org/10.1038/s41590-020-0769-3.CrossRefPubMed

46.

Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22:1264–75. https://doi.org/10.1038/s41556-020-0575-z.CrossRefPubMedPubMedCentral

47.

Zhang P, Cao L, Zhou R, Yang X, Wu M. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10(1):1495. https://doi.org/10.1038/s41467-019-09482-6.CrossRefPubMedPubMedCentral

48.

Xu Y, Chen C, Liao Z, Xu P. cGAS-STING signaling in cell death: mechanisms of action and implications in pathologies. Eur J Immunol. 2023. https://doi.org/10.1002/eji.202350386.CrossRefPubMed

49.

Zheng W, Feng D, Xiong X, Liao X, Wang S, Xu H, Le W, Wei Q, Yang L. The role of cGAS-STING in age-related diseases from mechanisms to therapies. Aging Dis. 2023. https://doi.org/10.14336/AD.2023.0117.CrossRefPubMedPubMedCentral

50.

Huang A, Zhou W. Mn-based cGAS-STING activation for tumor therapy. Chin J Cancer Res. 2023;35(1):19–43. https://doi.org/10.21147/j.issn.1000-9604.2023.01.04.CrossRefPubMedPubMedCentral

51.

Ferro M, Musi G, Marchioni M, Maggi M, Veccia A, Del Giudice F, et al. Radiogenomics in renal cancer management-current evidence and future prospects. Int J Mol Sci. 2023;24(5):4615. https://doi.org/10.3390/ijms24054615.CrossRefPubMedPubMedCentral

52.

Feng S. Gasdermins: making pores for pyroptosis. Nat Rev Immunol. 2021. https://doi.org/10.1038/s41577-021-00602-2.CrossRef

Title: Development and validation of a kidney renal clear cell carcinoma prognostic model relying on pyroptosis-related LncRNAs-A multidimensional comprehensive bioinformatics exploration
Authors: Chang Liu
Shuxin Dai
Hao Geng
Zhiwei Jiang
Xiangyu Teng
Kun Liu
Zhouting Tuo
Longfei Peng
Chao Yang
Liangkuan Bi
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01277-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Development and validation of a kidney renal clear cell carcinoma prognostic model relying on pyroptosis-related LncRNAs-A multidimensional comprehensive bioinformatics exploration

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Association between statin use on delirium and 30-day mortality in patients with chronic obstructive pulmonary disease in the intensive care unit

Early urate-lowering therapy in gouty arthritis with acute flares: a double-blind placebo controlled clinical trial

Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy

Resveratrol: a potential medication for the prevention and treatment of varicella zoster virus-induced ischemic stroke

Insights into research on myocardial ischemia/reperfusion injury from 2012 to 2021: a bibliometric analysis

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study